New hope for aggressive uterine cancer: drug combo trial launches

NCT ID NCT06795009

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 23 times

Summary

This study tests a new drug, zanzalintinib, combined with standard chemotherapy (paclitaxel) in people with recurrent high-grade uterine cancer. The goal is to find the safest and most effective dose and see if the combination can shrink tumors. About 36 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California, San Francisco

    NOT_YET_RECRUITING

    San Francisco, California, 94143, United States

    Contact Phone: •••-•••-••••

    Contact

  • University of New Mexico

    NOT_YET_RECRUITING

    Albuquerque, New Mexico, 87106, United States

    Contact Phone: •••-•••-••••

    Contact

  • University of Oklahoma

    NOT_YET_RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

    Contact Phone: •••-•••-••••

    Contact

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.